OSI sues Teva, Mylan for Tarceva patent infringement

Another day, another patent infringement lawsuit. Melville, NY-based OSI Pharmaceuticals says its suing Teva Pharmaceutical Industries and Mylan for trying to market generic versions of the daily cancer med Tarceva. Unless a court overturns the patent, OSI says the lawsuits will keep the FDA from approving Teva and Mylan's ANDAs until May 18, 2012. "OSI plans to vigorously protect and enforce the intellectual property rights of Tarceva," the company said in a statement.

Tarceva, a daily treatment for pancreatic and lung cancer, is marketed in the U.S. by OSI and Genentech.

- check out the OSI release

Related Articles:
Roche/Genentech file for broader Tarceva use
Roche cuts Tarceva price for U.K.
Tarceva linked with two patient deaths
Tarceva successful as maintenance therapy